A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS)
- DOI
- 10.1186/s13063-025-08895-7
- Published
- 2025-05-30
- Container
- Trials
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1186/s13063-025-08895-7,
title = {A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS)},
author = {Marlies Ostermann and David C. Corteville and Kent Doi and Jay L. Koyner and Andre Lamy and Gerry Li and Christine M. Solinsky and Pamela D. Winterberg and William T. Smith and Ravindra L. Mehta and Patrick T. Murray and Andrew D. Shaw and Alexander Zarbock and Daniel T. Engelman},
year = {2025},
journal = {Trials},
doi = {10.1186/s13063-025-08895-7},
url = {https://doi.org/10.1186/s13063-025-08895-7}
}RIS
TY - JOUR TI - A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS) AU - Marlies Ostermann AU - David C. Corteville AU - Kent Doi AU - Jay L. Koyner AU - Andre Lamy AU - Gerry Li AU - Christine M. Solinsky AU - Pamela D. Winterberg AU - William T. Smith AU - Ravindra L. Mehta AU - Patrick T. Murray AU - Andrew D. Shaw AU - Alexander Zarbock AU - Daniel T. Engelman PY - 2025 JO - Trials DO - 10.1186/s13063-025-08895-7 UR - https://doi.org/10.1186/s13063-025-08895-7 ER -
APA
Ostermann, M., Corteville, D. C., Doi, K., Koyner, J. L., Lamy, A., Li, G., Solinsky, C. M., Winterberg, P. D., Smith, W. T., Mehta, R. L., Murray, P. T., Shaw, A. D., Zarbock, A., & Engelman, D. T. (2025). A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS). Trials. https://doi.org/10.1186/s13063-025-08895-7
Source records
- crossref · retrieved 2026-09-27T03:14:33.643Z